Advertisement
Advertisement
U.S. markets open in 43 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Panbela Therapeutics, Inc. (PBLA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.0921-0.0145 (-13.60%)
At close: 04:00PM EST
0.0922 +0.00 (+0.11%)
Pre-Market: 08:39AM EST
Advertisement

Panbela Therapeutics, Inc.

712 Vista Boulevard
Suite 305
Waconia, MN 55387
United States
952 479 1196
https://www.panbela.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Dr. Jennifer K. Simpson C.R.N.P., CRNP, M.S.N., Ph.D.CEO, Pres & Director659.03kN/A1968
Ms. Susan HorvathVP of Fin., CFO, Sec. & Treasurer401.82kN/A1959
Ms. Tammy GroeneVP of OperationsN/AN/AN/A
Dr. Elizabeth Bruckheimer Ph.D.VP & Chief Scientific OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Corporate Governance

Panbela Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement